Eli Lilly To Spend $5 Billion On Virginia Plant To Boost U.S. Drug Manufacturing Capacity

Eli Lilly will invest $5 billion to build a manufacturing facility in Goochland County, Virginia, to expand production of targeted cancer drugs and other treatments, according to CNBC. The pharmaceutical giant plans to invest $27 billion in four new U.S. manufacturing plants, with three additional sites to be announced this year and all operational within five years. Drugmakers are increasing U.S. production as Trump threatens tariffs on imported pharmaceuticals to push companies to re-shore manufacturing. Eli Lilly said its new Virginia plant will produce active ingredients for cancer and autoimmune drugs, marking its first dedicated site for bioconjugates and monoclonal antibodies. CEO Dave Ricks said the new site will provide needed capacity to produce biologics and antibody drug conjugates in-house, including final drug product manufacturing.